C.R. Bard, Inc. v. Medtronic, Inc.

140 F. Supp. 2d 346, 2001 U.S. Dist. LEXIS 8432, 2001 WL 434388
CourtDistrict Court, D. Delaware
DecidedApril 23, 2001
DocketCiv.A. 96-589-SLR
StatusPublished

This text of 140 F. Supp. 2d 346 (C.R. Bard, Inc. v. Medtronic, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
C.R. Bard, Inc. v. Medtronic, Inc., 140 F. Supp. 2d 346, 2001 U.S. Dist. LEXIS 8432, 2001 WL 434388 (D. Del. 2001).

Opinion

MEMORANDUM OPINION

SUE L. ROBINSON, Chief Judge.

I. INTRODUCTION

Pending before the court is the proper interpretation of the mandate rendered by the United States Court of Appeals for the Federal Circuit in this case. 1 (D.I.193) C.R Bard, Inc. v. Medtronic, Inc., No. 99-1475, 2000 WL 868581 (Fed.Cir. June 29, 2000)). According to the Federal Circuit, it is appropriate to consult the opinion delivered by the Court at the time its mandate was rendered in order to ascertain what was intended by the mandate. See Laitram Corp. v. NEC Corp., 115 F.3d 947, 952 (Fed.Cir.1997). With that prinei- *348 pie in mind, the procedural posture of this case shall be reviewed.

II. BACKGROUND

Plaintiff C.R. Bard, Inc. (“Bard”), the assignee of U.S.Patent No. 5,484,474 (“the ’474 patent”), sued defendant Med-tronic, Inc. (“Medtronic”) for infringement of the ’474 patent. The ’474 patent is directed to a filter for removing gas bubbles and particulate material from liquid, particularly from blood. The issues of infringement and validity were tried to a jury. The jury found that Medtronic infringed claims 1, 3-6, 8, 10-13, and 15 of the ’474 patent 2 under the doctrine of equivalents, that its infringement was willful, and that the patent was not invalid for anticipation or obviousness. The jury awarded damages to Bard in the amount of $3,277,534.00. Medtronic moved for judgment as a matter of law (“JMOL”) that it did not infringe the patent and that the patent was invalid for obviousness, which motion was denied by this court. Medtronic then appealed the denial of its JMOL.

Specifically, on appeal Medtronic challenged this court’s construction of the “housing” and “filter element support” limitations of the claims. With respect to the housing limitation, this court accepted Bard’s assertion that a substantially toroidal flow can occur in a non-toroidal housing, and construed the phrase as requiring “that the housing (although not necessarily toroidal in shape) must determine with precision a fluid flow path having the shape of a substantially closed curve which rotates about, but does not intersect or contain, an axis in its own plane.” C.R. Bard, Inc. v. Medtronic, Inc., 1999 WL 458305, at *1, 1999 U.S.Dist. LEXIS 9875 at *3 (D.Del.1999). The Federal Circuit rejected this construction, finding instead that,

[although the patent states that “shapes other than a toroid may be used for further embodiments,” id. at col. 4, 11. 18-19, it does not indicate that a housing of any other shape would “define a substantially toroidal flow path,” as recited in the claims. The only structure described in the patent as providing a to-roidally shaped flow path is a toroidally shaped housing. We therefore construe the “housing” limitation as requiring that the housing itself be toroidally shaped.

C.R. Bard, Inc. v. Medtronic, Inc., 2000 WL 868581 at *3, 2000 U.S.App. LEXIS 15316 at *8 (Fed.Cir.2000). 3

*349 This court also construed the “filter element support located within the housing and centrally disposed with respect to the toroidal flow path” limitation. Accepting once again Bard’s construction, this court determined that the term “support” included “the upper and lower potting material,” but did not require “support from the top by a structure descending from the housing cap.” C.R. Bard, Inc. v. Medtronic, Inc., C.A. No. 96-589-SLR, slip op. at 20 (D.Del. May 7, 1998) (Memorandum Order). Once again, the Federal Circuit rejected this construction.

In view of the teachings in the ’474 patent and the prosecution history surrounding the addition of this limitation to the claims, we construe the “filter element support” limitation as requiring a structural support for the filter element (not just potting material) that is centrally disposed with respect to the toroidal flow path, at the top of the filter element.

C.R. Bard, 2000 WL 868581 at *4-5, 2000 U.S.App. LEXIS at *14-15. The Federal Circuit concluded:

Because the jury verdict as to Med-tronic’s infringement of the ’474 patent and the district court’s denial of Med-tronic’s request for JMOL of nonin-fringement were based on an erroneous claim construction, we vacate the judgment of infringement and the denial of Medtronic’s JMOL of noninfringement, and remand for a determination of the infringement issue under the correct claim construction.

Id. at *5, 2000 U.S.App. LEXIS at *15. The mandate rendered by the Federal Circuit in this case reads:

For the foregoing reasons, we vacate the judgment of infringement and the district court’s denial of Medtronic’s JMOL of noninfringement and affirm the district court’s denial of Medtronic’s JMOL of invalidity. We remand the case to the district court for further proceedings consistent with this opinion.

Id. at *7, 2000 U.S.App. LEXIS at *19.

On remand, Medtronic filed a renewed motion for JMOL on noninfringement. In support of its motion, Medtronic argues that, because its filter’s housing is not toroidally shaped, there can be no literal infringement. Bard does not contest this assertion. Medtronic goes on to argue, however, that

[tjhere is no infringement under the doctrine of equivalents because the function of the toroidal housing is to add more surfaces than a simple cylindrical structure, so that the additional surfaces can constrain the blood to flow in a toroid. No such additional surfaces are present in the Medtronic device.

(D.I. 204 at 2-3) With respect to the “filter element support” limitation, Medtronic argues that its filter

does not have a filter element support in the space between the filter cap and the ceiling of the housing because “the space between the filter cap and the housing cap is empty.” Consequently, there is no literal infringement. There is no infringement under the doctrine of equiva *350 lents because no element in the Med-tronic filter performs the same function as the filter element support. Bard’s patent identifies this function as providing support for the filter element by attaching it to the top of the housing to obviate the need for a central core. Medtronic’s device has no such element and in fact utilizes a central core.

(D.I. 204 at 3)

Bard responded, first, by arguing that [t]he Federal Circuit’s new claim constructions require a new trial. On its appeal, Medtronic requested from the Federal Circuit the very same relief that it is now seeking from this Court. The Federal Circuit did not grant Medtronic’s request.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
140 F. Supp. 2d 346, 2001 U.S. Dist. LEXIS 8432, 2001 WL 434388, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cr-bard-inc-v-medtronic-inc-ded-2001.